Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Core Insights - Analysts project that PTC Therapeutics (PTCT) will report a quarterly loss of $0.96 per share, reflecting a 300% decline year over year [1] - Revenue is expected to reach$ 252.51 million, a decrease of 17.8% from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a reevaluation of initial estimates by analysts [1][2] Revenue Projections - Analysts estimate that 'Revenues- Net product revenue' will be $141.85 million, showing an 8.5% decline from the previous year [4] - 'Revenues- Royalty revenue' is projected to reach$ 73.16 million, indicating a significant increase of 43.4% year over year [4] - 'Revenues- Net product revenue- Emflaza' is expected to be $50.95 million, reflecting a 24.4% decrease [5] - 'Revenues- Net product revenue- Translarna' is projected at$ 78.77 million, showing a 4.8% increase from the same quarter last year [5] Market Performance - PTC Therapeutics shares have increased by 9.1% over the past month, contrasting with a -0.5% change in the Zacks S&P 500 composite [6] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [6]